Loading stock data…
$64.95+1.66 (+2.61%)
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
BridgeBio Pharma, Inc. in the Healthcare sector is trading at $64.80 with a market capitalization of $13.2B. Wall Street consensus targets $109.05 (21 analysts), implying a +68.3% move over the next 12 months. The stock is currently 31% below its 52-week high of $93.42, remaining 11.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $243.68M↑ | $194.51M↑ | $154.18M↑ | $120.70M↑ | $110.56M |
| Gross Profit | $228.63M↑ | $184.58M↑ | $146.07M↑ | $114.14M↑ | $106.91M |
| Operating Income | -$107.08M↓ | -$105.96M↑ | -$128.43M↑ | -$136.36M↓ | -$133.47M |
| Net Income | -$152.22M↑ | -$164.04M↑ | -$192.86M↓ | -$182.74M↓ | -$181.90M |
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of c...